1. To determine the feasibility of integrating a PGx panel test in the EMR with a pharmacist PGx e-consult. 2. Determine the fidelity to genotype-guided pharmacotherapy recommendations. 3. To determine if PGx testing will improve the patient self-reported numeric pain scores 4. To determine if PGx testing will reduce MME 5. To determine if PGx testing will decrease ADRs resulting from their pain regimen. 1. The proportion of PGx test results returned prior to surgery. 2. The proportion of dose modifications and medication selections made in agreement with the genotype-guided dosing recommendations for analgesic medications. [Time Frame: up to 14 days after surgery] 1. Mean patient self-reported numeric pain scores on POD 0, 1, & 2 (only while admitted) and POD 3, 7, & 14 among variant carriers in each group. [Time Frame: 14 days after surgery] 2. The total MME consumption between intervention and control groups among variant carriers on POD 0-7 and POD 1-14). [Time Frame: 14 days after surgery] 3. The frequency of pain medication related ADRs among variant carriers. 4. Length of hospital admission (LOS) 5. Baseline provider attitudes toward and knowledge of PGx testing as assessed by a questionnaire. [Time Frame: Prior to start of study and provider education] 6. Post-study patient experience with PGx testing as assessed by a questionnaire. [Time Frame: 30 days after surgery] 7. The frequency of actionable variants by ancestry

You may be eligible for this study if you meet the following criteria:

• Conditions: Medical Research
• Age: 99 years or below
• Gender: All